Thermo Fisher Scientific, Genome Canada and the Ontario Institute for Cancer Research signed a three-year agreement to develop three targeted next-generation sequencing-based assays and analysis software. Under the terms of the $4.5 million deal, assays for rapid diagnosis of pancreatic cancer and prostate and breast cancer treatment will be used to evaluate DNA and gene expression signatures for cancer driver mutations and for patient stratification in clinical studies.
Thermo Fisher enters cancer NGS assay deal with Genome Canada, OICR
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.